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Background: Gleditsia sinensis thorns have been widely used in traditional Korean medicine for the treatment of
several diseases, including obesity, thrombosis, and tumor-related diseases. The aim of the study is to determine the
antiangiogenic effect of Gleditsia sinensis thorns in vitro and in vivo in a bid to evaluate its potential as an anticancer
drug.
Methods: Ethanol extract of Gleditsia sinensis thorns (EEGS) were prepared and used for in vitro and in vivo assays.
In vitro antiangiogenic effect of EEGS was determined in HUVEC primary cells by cell migration and tube formation
assays. In vivo antiangiogenic effect of EEGS was determined by measuring vessel formation and vascular
endothelial cells migrating into the implanted matrigels in nude mice. The angiogenesis-related proteins of which
expression levels were altered by EEGS were identified by proteomic analysis.
Results: EEGS exerted a dose-dependent antiproliferative effect on HUVEC cells without significant cytotoxicity.
Angiogenic properties, such as cell migration and tube formation, were significantly inhibited by EEGS in a
dose-dependent manner. New vessel formation was also suppressed by EEGS, as determined by the directed in vivo
angiogenesis assays in nude mice. EEGS reduced the expression of proangiogenic proteins, endothelin 1 and matrix
metallopeptidase 2, in HUVEC cells.
Conclusions: Our findings suggest that EEGS can inhibit angiogenesis by down-regulating proangiogenic proteins,
and therefore it should be considered as a potential anticancer drug targeting tumor-derived angiogenesis.
Keywords: Gleditsia sinensis thorn, Antiangiogenesis, Anticancer, Gene expression, Medicinal herbBackground
Angiogenesis is the physiological process of forming new
blood vessels from the preexisting vasculature, and it is
a vital process during embryonic development. However,
in adults angiogenesis is only observed in specific areas,
such as the endometrium and ovarian follicle cells [1].
Angiogenesis also plays a key role in many diseases,
including cancer, where it promotes tumor growth and
metastasis [2]. A continuous supply of nutrients and
oxygen is critical for tumor growth; however, these fac-
tors are severely limited in the interior of solid tumors,
and the tumor core undergoes apoptotic death in the
absence of new blood vessels. Moreover, suitable tumor
vasculature is also important for removing the metabolic
waste produced by tumors, to maintain normal metabolic* Correspondence: nosookim@kiom.re.kr
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reproduction in any medium, provided the orprocesses and for tumor development [3]. In fact, the
volume of a tumor cannot exceed >1 mm3 in an avascular
state [4]. Therefore, the inhibition of angiogenesis is a
promising strategy for anticancer drug development.
Since 1971, when Folkman hypothesized that tumor
growth is dependent on angiogenesis [5], considerable
efforts have been dedicated to develop cancer therapies
that target angiogenesis. Because angiogenesis is a multi-
step and multi-factorial process, each step or factor could
be a target of antiangiogenic cancer therapy. Current anti-
angiogenic therapies include natural angiogenesis inhibi-
tors (e.g., angiostatin), endothelial cell growth inhibitors
(e.g., TNP-470), inhibitors of proangiogenic molecules
(e.g., vascular endothelial growth factor [VEGF] receptor
antibodies), and therapies that interfere with basement
membranes and the extracellular matrix (e.g., tissue inhi-
bitors of matrix metallopeptidases [TIMPs]) [2]. Endothe-
lial cells have low mutagenesis rates and are unable tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing angiogenesis an attractive anticancer target [4]. An
additional advantage is the ability of antiangiogenic drugs
to target newly forming vessels without harming sur-
rounding normal cells; therefore, they show lower toxici-
ties than traditional cytotoxic chemotherapeutics. Thus
cancer patients may be able to receive repeated cycles of
therapy without serious side effects [6]. In addition, anti-
angiogenic cancer drugs have the potential to treat a wide
range of solid tumors because most tumors require
neovasculature for propagation and metastasis. Previous
studies have demonstrated that cancer cells release proan-
giogenic proteins, such as VEGF [7] and basic fibroblast
growth factor (FGF2) [4]. These growth factors recruit
endothelial cells and promote their proliferation. There-
fore, small molecules that interfere with the proangiogenic
signaling pathway are potential anticancer drugs.
Traditional oriental medicine has used various parts
of Gleditsia sinensis such as thorns, fruits, and anomal-
ous fruits (fruits without seeds) to treat diverse diseases
including thrombosis, obesity, and tumor-related dis-
ease [8-10]. In oncologic aspect the extract of Gleditsia
sinensis thorn could prevent colon cancer in vitro and
vivo through the induction of G2/M cell cycle arrest
and extracellular signal-regulated kinase 1/2 (ERK1/2)
activation [10], and cervical cancer in vivo through
down-regulation of proliferating cell nuclear antigen
(PCNA) and mutant p53 [11]. The extract of anomalous
fruits of Gleditsia sinensis induced apoptotic cell death
in primary leukemic cells of cancer patients [12]. In
addition the extract of Gleditsia sinensis fruits showed
anticancer effects in esophageal squamous cell carcin-
oma cell lines by inhibiting cyclooxygenase 2 (COX2)
expression and telomerase activity [13]. The extract of
Gleditsia sinensis thorn was also known to have anti-
atherogenic effect in vascular smooth muscle cells by
inhibiting cell proliferation and TNFα-induced matrix
metallopeptidase 9 (MMP9) expression [14]. However,
the effect of EEGS on angiogenesis and its underlying
mechanism are still in question in primary endothelial
cells that form blood vessels. In this study, we demon-
strated that the EEGS has antiangiogenic potential both
in vitro and in vivo.
The thorn of Gleditsia sinensis L. (family Leguminosae)
has been widely used in traditional Chinese and Korean
medicine for the treatment of several diseases, including
obesity, thrombosis, and tumor-related diseases [9,10]. Lee
et al. demonstrated that ethanol extract of the Gleditsia
sinensis thorn (EEGS) showed antiproliferative potential in
colon cancer cell lines in vitro and in vivo by inducing
cancer cell growth arrest in the G2/M phase [10]. How-
ever, the effect of EEGS on angiogenesis and its underlying
mechanism are unknown in primary endothelial cells




Gleditsia sinensis thorns were purchased from Kwang-
myungdang Medicinal Herbs (Ulsan, Republic of Korea)
in July 2010. Identity of the Gleditsia sinensis thorns was
confirmed by Dr. Go Ya Choi, Basic Herbal Medicine
Research Group, Herbal Medicine Research Division,
Korea Institute of Oriental Medicine (KIOM). A voucher
specimen (KIOM-CRC-1) was deposited at KM-Based
Herbal Drug Research Group, Herbal Medicine Research
Division, KIOM, Republic of Korea. Dried Gleditsia sinensis
thorns (200 g) were finely pulverized and immersed in
70% (v/v) ethanol (100 g/L). The solvent extraction was
performed by subjecting the mixtures to two consecutive
1 h periods of ultrasonication. The extracts were filtered
through Whatman No.2 filter paper and concentrated in a
rotary evaporator. The powdered extract (11.03 g) was
homogenized using a mortar and stored at 4°C. The yield
of the final extract was approximately 5.52% (w/w).
Cell culture
Human umbilical vein endothelial cells (HUVEC) were
obtained from Lonza (Walkersvill, MD, U.S.A.). They
were maintained in EGM-2 endothelial growth medium
(Lonza) containing 2% fetal bovine serum (FBS), 0.4%
FGF2, 0.1% VEGF, 0.1% R3-insulin-like growth factor 1
(R3-IGF1), 0.1% epidermal growth factor (EGF), 0.04%
hydrocortisone, 0.1% ascorbic acid, 0.1% heparin, and
0.1% GA-1000 at 37°C in a humidified atmosphere con-
taining 5% CO2. The culture medium was replaced with
fresh medium every other day, and the cells were used
for experiments between passage number 5 and 10.
Cell viability
Because the crude ethanol extracts were insoluble in
water, EEGS was dissolved in dimethyl sulfoxide (DMSO,
Sigma, St Louis, MO, U.S.A.) at a concentration of 20 mg/
mL and stored at −70°C until use. One day before drug
treatment, 5 × 103 cells were seeded into each well of a
24-well tissue culture plate that contained 450 μL of
EGM-2. The cells were then treated with 50 μL of serially
diluted test drugs and maintained for various periods. The
higher maximum concentration of vehicle (1%) than usual
(0.1-0.5%) was used in this study due to low solubility of
EEGS. However, we found that neither cell viability nor
in vitro angiogenesis of HUVEC cells was significantly
affected by DMSO up to 1%. Drug-treated HUVEC cells
were trypsinized and resuspended in cultured medium.
The numbers of total (viable and dead) and dead cells
were determined using an ADAM-MC automatic cell
counter (NanoEnTek, Seoul, Republic of Korea). In brief,
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with a DNA staining fluorescent dye (propidium iodide,
PI), and AccuStain N solution is a saline solution contain-
ing only PI. The numbers of total (viable and dead) and
dead cells were counted by mixing an equal volume of cell
suspension with AccuStain T and AccuStain N, respect-
ively, and by loading 20 μL of mixed solution into the T
and N channels of AccuChip. The number of total cells
and the cell viability were automatically calculated by
ADAM-MC software.
Wound healing assay
HUVEC cells, cultured in 24-well plates, were scratched
with a yellow tip at 90% confluence and photographs
were taken using an inverted microscope (Olympus
IX71, Tokyo, Japan). Cells were washed with fresh
EGM-2 and further incubated in fresh EGM-2 with va-
rious concentrations of EEGS. After 12 h, photographs
were taken and wound healing was digitally quantified
using MetaMorph image analysis software (Molecular
Devices, Downingtown, PA, U.S.A.). The healing area
(%) was calculated according to the following formula:
healing area (%) = [1-wounded area (t=12 h)/wounded
area (t = 0 h)] × 100.
Tube formation assay
The antiangiogenic potential of EEGS was tested using
a Cultrex in vitro angiogenesis assay kit (Trevigen,
Gaithersburg, MD, U.S.A.) according to the manufac-
turer’s instructions. One hundred microliters of HUVEC
cells (1.5 × 105 cells/mL) were resuspended in EGM-2
with various concentrations of EEGS and added to a 96–
well plate that was precoated with basement membrane
extracts (BME). After 12 h cultivation at 37°C, tubes were
photographed using a microscope. Sulforaphane (5 μM)
was included in the tube formation assay as a positive
control [15]. The tube length and branch points were
digitally quantified using MetaMorph image analysis
software.
In vivo angiogenesis assay
In vivo angiogenesis was assayed using the directed
in vivo angiogenesis assay (DIVAA) kit (Trevigen)
according to the manufacturer’s instructions. In brief,
angioreactors, silicone cylinders closed at one end, were
filled with growth factor-reduced BME premixed with
combination of angiogenic factors (VEGF, FGF2) and dif-
ferent concentrations of EEGS (0, 50, 100 and 200 μg/ml).
Angioreactors were inverted and incubated at 37°C for 1 h
to allow gel formation before subcutaneous implantation
into the dorsal flanks of the 6-week-old nude mice. After
12 days, the angioreactors were harvested and vessel for-
mation was photographed. Vascular endothelial cells mi-
grating into the BME to form vessels in the angioreactorwere quantified by FITC-lectin detection. The fluores-
cence intensity was measured at a wavelength of excitation
485 nm and emission 510 nm with a fluorescence micro-
plate reader (SPECTRA MAX GEMINI EM, Molecular
Devices). The fluorescence intensity is proportional to the
number of endothelial cells migrating into the BME gels
of implanted cylinder. The relative angiogenesis were nor-
malized to the mean of the positive control. All experi-
ments involving mice were approved by the Institutional
Animal Care and Use Committee at the Korea Institute of
Oriental Medicine (Protocol # 12–058).
Proteomic analysis
HUVEC cells were cultured in 100-mm tissue culture
dishes containing EGM-2 media until they reached
75-80% confluence. The cells were washed with PBS
and incubated in EGM-2 media with or without EEGS
for the indicated times. The cultured medium was col-
lected and centrifuged for further analysis. The cells
were rinsed with ice cold PBS and solubilized in lysis
buffer (1% NP-40, 20 mM Tris–HCl, pH 8.0, 137 mM
NaCl, 10% glycerol, 2 mM EDTA, 10 μg/mL aprotinin,
10 μg/mL pepstatin and 10 μg/mL leupeptin) by gentle
rocking at 4°C for 30 min. The insoluble debris was
removed by centrifugation at 14,000 × g for 5 min at 4°C,
and the soluble fractions were collected. Protein concen-
trations were determined using the BCA protein assay kit
(Pierce, Rockford, IL, U.S.A.), and 200 μg of cell lysate or
100 μL of culture supernatant were incubated with human
angiogenesis array membranes (Proteome Profiler™, R&D
Systems). The proteome profiles were developed accord-
ing to the manufacturer’s instructions. Membrane-bounds
proteins were visualized using Supersignal west femto
chemiluminescent substrates (Pierce), and the images
were captured on a Fusion SL4 imaging system (Fisher
Biotec, Wembley, Australia).
Immunoassay
The amount of endothelin 1 (EDN1) released from
HUVEC cells was quantified using the human EDN1 im-
munoassay kit (R&D Systems, Minneapolis, MN, U.S.A.)
according to the manufacturer's instructions. In brief, cul-
tured medium was centrifuged to remove particulates and
the supernatants were aliquoted and stored at −20°C. The
recombinant EDN1 standards and samples were loaded
into separate wells of a microplate that was precoated with
an EDN1 monoclonal antibody, and the samples were
incubated for 1 h at room temperature (RT). After wash-
ing, EDN1 conjugates were added to each well and incu-
bated for 3 h at RT. After washing, a substrate solution
was added and incubated for 30 min. Color development
was monitored using a microplate reader (Emax, Molecu-
lar Devices) at 450 nm, and the concentration of EDN1
was calculated from the standard curve.
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The activity of matrix metallopeptidase 2 (MMP2) was
determined using a gelatin zymogram as previously
described [16]. In brief, cultured medium was centri-
fuged at 1,000 rpm for 5 min at 4°C to remove cellular
debris. The supernatants were then concentrated using
a Vivaspin 6 (GE healthcare, Piscataway, NJ, U.S.A.)
with a molecular weight cutoff size of 5 kDa. The pro-
tein concentration of the medium was quantified using
a 2D quant kit (GE healthcare), and 30 μg of protein
was mixed with SDS-PAGE loading buffer without redu-
cing agent. The protein samples were incubated at 24°C
for 30 min and separated on a 7.5% SDS-PAGE gel
copolymerized with 1 mg/mL gelatin (Sigma). The gels
were washed three times (30 min at 24°C) with 2.5%
(v/v) Triton X-100 to remove SDS, and then incubated
in a buffer composed of 50 mM Tris (pH 7.6), 1 μM
ZnCl2, and 5 mM CaCl2 for 18 h at 37°C. The gels were
stained with 0.1% Coomassie blue solution.
Real-time polymerase chain reaction (RT-PCR)
TaqMan RT-PCR was performed to determine the effect
of the EEGS on intracellular mRNA levels of EDN1 and
MMP2. Total RNA was prepared from HUVEC cells
that had been cultured in the presence or absence of
EEGS using the Easy-spin™ total RNA extraction kit
(iNtRON biotechnology, Seoul, Republic of Korea). The
integrity of the isolated total RNA was confirmed by
agarose gel electrophoresis. Single-stranded cDNA was
synthesized from 5 μg of total RNA using the Super-
Script™ III first strand synthesis system (Invitrogen,
Carlsbad, CA, U.S.A.). Pre-validated probe and primer
sets for EDN1 (ABI ID, Hs00174961_m1; FAM-labeled),
MMP2 (ABI ID, Hs01548727_m1; FAM-labeled), and
β-actin (ABI ID, Hs99999903_m1; VIC-labeled) were
purchased from Applied Biosystems (Foster City, CA,
U.S.A.). The PCR reaction and determination of the rela-
tive expression of specific genes were carried out in the
Applied Biosystems Sequence Detection System 7500.
Statistics
The differences in continuous variables were determined
by a one-way analysis of variance (ANOVA) and Tukey’s
HSD post-hoc test. Statistical significance was set at
p<0.05.
Results
EEGS inhibits cell proliferation but does not induce cell
death in HUVEC cells
Proliferation of endothelial cells in response to angiogenic
stimuli is a critical step during new vessel formation [17].
To determine the effect of EEGS on HUVEC cell growth,
HUVEC cells were cultured in EGM-2 media containing
endothelial growth factors and exposed to increasingconcentrations of EEGS (0–200 μg/mL). At regular time
intervals, total (viable and dead) cell numbers and viability
were calculated using an automatic cell counter that
assessed the cytoplasmic membrane integrity as described
in the Methods. As shown in Figure 1A, EEGS treatment
inhibited cell proliferation in a dose-dependent manner. A
significant inhibitory effect on cell proliferation was
observed in response to EEGS at ≥50 μg/mL concentra-
tions. The highest dose (200 μg/mL) of EEGS inhibited
cellular proliferation completely throughout the 48 h
cultivation period. However, the antiproliferative effect
of EEGS was not related to cytotoxicity (Figure 1B).
Although a slight decrease in cell viability was observed in
the EEGS-treated HUVEC cells, no significant cytotoxicity
was observed at doses of up to 200 μg/mL EEGS during
the 48 h cultivation period. The antiproliferative potential
of EEGS was also observed under the microscope
(Figure 1C). Although increasing concentrations of EEGS
induced morphological changes and growth arrest, signifi-
cant cell death was not observed during 48 h of treatment.
EEGS inhibits angiogenic properties in HUVEC cells
in vitro
Angiogenesis mediated by vascular endothelial cells is
characterized by cell migration to designated sites of
new blood vessel formation. Thus, the antiangiogenic
potential of EEGS in HUVEC cells was determined using
an in vitro wound healing assay. In the absence of EEGS
treatment, HUVEC cells found at the border of scratches
(Figure 2A, left panel, T = 0) migrated rapidly toward
the wounded area and covered it within 12 h (0 μg/mL
of EEGS). However, cell mobility was slowed by EEGS
treatment in a dose-dependent manner, and HUVEC
cells treated with 200 μg/mL of EEGS showed no move-
ment. A significant decrease in cell mobility was observed
at a concentration of ≥50 μg/mL, and only 10% of the
wound was covered at an EEGS concentration of 200 μg/
mL (Figure 2A, right panel). In addition, we evaluated the
effect of EEGS treatment on tube formation by HUVEC
cells. On a matrix-coated surface, HUVEC cells are cap-
able of building tubes via connecting to neighboring cells
in the presence of growth factors (Figure 2B, left panel, 0
μg/mL of EEGS). However, in the presence of EEGS, the
intercellular connection was limited and HUVEC cells
failed to form tubes. To quantify the degree of tube forma-
tion, photographs were taken at the end of each experi-
ment under the microscope, and tube length and branch
numbers were calculated using image analysis software
(Figure 2B, right panel). Both parameters decreased in a
dose-dependent manner following EEGS treatment. Statis-
tical analyses revealed that both tube length and branch
number were significantly reduced at ≥100 μg/mL con-
centrations of EEGS. The inhibitory effect of 100 μg/mL
of EEGS on HUVEC cell tube formation was comparable
EEGS treatment (h)
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Figure 1 Antiproliferative effect of EEGS in HUVEC cells. Exponentially growing HUVEC cells were treated with various concentrations (0–200
μg/mL) of EEGS for the indicated time periods. The total cell number (A) and viability (B) were determined as described in the Methods. The
effect of EEGS on HUVEC growth and morphological changes were observed under the microscope at 200 x magnification (C). The data are
presented as the mean±S.D. of at least three independent experiments. Statistical analysis was performed at the 48 h time point. *p<0.05 and
***p<0.001 compared with control treatment.
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formation inhibition.
EEGS inhibits angiogenesis in vivo
Because EEGS inhibited in vitro angiogenic properties,
such as cell migration and tube formation, we next
investigated its effect on angiogenesis in vivo using
commercially available direct in vivo angiogenesis kit as
described in Methods. As shown in Figure 3 (top panel),
massive vessel ingrowth from the open ends of angior-
eactors was observed in the presence of VEGF/FGF2
angiogenic factors but in the absence of EEGS (positive
control). However, EEGS treatment suppressed the vessel
ingrowth induced by angiogenic factors in a dose-
dependent manner as determined by FITC-lectin label-
ing of endothelial cells to form new vessels (bottom
panel). Antiangiogenic effect of EEGS was observed at
≥50 μg/mL concentration and complete inhibition of
vessel formation was observed at 200 μg/mL of EEGS.
New vessel formation was limited in the absence of
both VEGF/FGF2 and EEGS (negative control).
EEGS down-regulates the expression of proangiogenic
proteins
To identify proteins of which expression levels are altered
in response to EEGS treatment, a proteomic analysis was
carried out using cultured media or cell lysates prepared
from HUVEC cells that had been treated with 100 μg/mL
EEGS or vehicle for 8 h. Membranes arrayed with specificantibodies for angiogenesis-related proteins were incu-
bated with cultured medium or cell lysates, and the pro-
tein expression profiles were compared by analyzing dot
intensities (Figure 4A). We observed significant changes
in the protein expression of FGF2 and EDN1. Treatment
of 100 μg/mL EEGS decreased the EDN1 expression by
34.8% (p<0.001) in the cultured media, and by 55.2%
(p<0.001) in the cell lysate compared with the negative
vehicle control. Because the expression of FGF2, which
was supplemented in EGM-2 endothelial growth medium,
was decreased by EEGS only in cultured media (41.7%,
p<0.01) but not in the cell lysate (122.5%, p=0.210), it was
excluded from our further studies. It is possible that
HUVEC cells treated with EEGS may consume FGF2
more rapidly than HUVEC cells treated with DMSO by an
unknown mechanism. The proangiogenic protein, EDN1,
showed the most dramatic and reproducible change in
protein levels in both cell lysate and cultured media. To
verify the EEGS-induced EDN1 down-regulation observed
in the proteomic analysis, we performed an EDN1 im-
munoassay using a commercially available kit (Figure 4B,
left panel). Without EEGS treatment, extracellular EDN1
increased continuously throughout the culture period.
However, in the presence of EEGS, the rate of EDN1
production decreased in a dose-dependent manner.
Treatment with 200 μg/mL EEGS almost completely
inhibited EDN1 production after 4 h. Next, we deter-
mined the effect of EEGS treatment on the level of
intracellular EDN1 mRNA using RT-PCR. Total RNA








































































Figure 2 Inhibitory effect of EEGS on angiogenic properties in HUVEC cells. (A) HUVEC cells at 90% confluence were scratched with pipette
tips and cultured with various concentrations (0–200 μg/mL) of EEGS for 12 h. The healing areas covered by migrated cells (left) was calculated
using image analysis software (right). The data are presented as percentages of the healed area compared to the initial scratched area (t = 0).
(B) HUVEC cells were plated in a 96-well plate that was precoated with BME, and the cells were subsequently treated with various concentrations
(0–200 μg/mL) of EEGS. After 12 h, the tubes were photographed under the microscope at 100 x magnification (left). Tube length and branch
numbers were measured using image analysis software (right). Sulforaphane (Sulfo, 5 μM) was used as a positive control for inhibition of tube
formation. The data are presented as relative means compared with control treatment. Data are presented as the mean±S.D. of at least three
independent experiments. **p<0.01, and ***p<0.001 compared with control treatment.
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treated with increasing concentrations (0–200 μg/mL)
of EEGS for 8 h. EEGS treatment reduced the level of
intracellular EDN1 mRNA in a dose-dependent manner
(Figure 4B, right panel), and 200 μg/mL of EEGS
decreased EDN1 mRNA levels by more than 90%. These
data suggest that EEGS down-regulates EDN1 mRNA
levels, leading to reduced EDN1 production.
MMP2 and MMP9 are key enzymes involved in angio-
genesis during cancer development. Proteomic analysis
revealed no change in MMP9 expression following EEGS
treatment. However, MMP2 was not arrayed on the prote-
ome membrane chip, and therefore we investigated the ef-
fect of EEGS on the activity of MMP2 in HUVEC cell
cultured media using zymogram. MMP2 can hydrolyze a
gelatin substrate incorporated into an SDS-PAGE gel,
and gelatin hydrolysis by MMP2 can be visualized by
Coomassie staining. The activity of MMP2 in the zymo-
gram was decreased by EEGS in a dose-dependent
manner (Figure 4C, left panel). Western blot analysis
revealed that reduced MMP2 activity correlated with a
decrease in the level of MMP2 protein secreted into thecultured medium. To further understand the EEGS-
induced reduction in MMP2 activity, the intracellular
mRNA levels of MMP2 were investigated using RT-PCR.
Total RNA and cDNA were prepared from HUVEC
cells that were treated with increasing concentrations
(0–200 μg/mL) of EEGS for 8 h. Intracellular mRNA
levels of MMP2 were reduced in a dose-dependent
manner (Figure 4C, right panel), which may explain the
decrease in MMP2 activity in cultured media, as shown
in the zymogram.
Discussion
Although massive tumors can be treated by surgical
intervention, treatment of small primary tumors or can-
cers undergoing metastasis largely relies on chemother-
apy [4]. However, the clinical use of cytotoxic cancer
drugs, which target uncontrolled, dividing cancer cells,
is limited by the severe side effects caused by killing fast
dividing normal cells, such as blood cells. Therefore,
many cytotoxic cancer drugs currently in development
are designed to attack only cancer cells. This targeted
therapy is achieved by conjugating cytotoxic drugs with
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Figure 3 The antiangiogenic effects of EEGS in vivo.
Angioreactors filled with BME premixed with combination of VEGF/
FGF2 angiogenic factors and increasing concentrations of EEGS
(0–200 μg/mL) were implanted into the dorsal flank of nude mice.
After 12 days, the implanted cylinders were harvested (upper), and
vascular endothelial cells migrated into the BME gels of bioreactors
were quantified by FITC-lectin detection (lower). Negative control
represents the bioreactors without VEGF/FGF2 angiogenic factors.
The relative angiogenesis (%) were normalized to the mean of the
VEGF/FGF2-treated positive control. Data are presented as the
mean±S.D. of four cylinders per group. **p<0.01 compared with
positive control.
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molecules. However, a disadvantage of these “magic bul-
let” cancer drugs is that they demonstrate variable effi-
cacy depending on the cancer type and the genetic
background of the patient [18,19]. Another limitation of
cytotoxic anticancer drugs is that these chemicals can
induce drug resistance in cancer cells as a result of
tumor drug efflux [20]. Therefore, the drug dose may
need to be increased to induce the same therapeutic
response over time.
New blood vessel formation, or angiogenesis, is import-
ant for many physiological processes throughout the en-
tire human lifespan, including fetal development. It is also
critical for tumor development, as first suggested almost
40 years ago by Folkman [5,21]. Anticancer drugs devel-
oped to inhibit angiogenesis have been demonstrated to
inhibit tumor growth by targeting molecules within the
angiogenic signaling pathway. Bevacizumab (trade name,
AVASTINW, Genentech/Roche), a monoclonal antibody
raised against human vascular endothelial growth factor A
(VEGFA) inhibits the VEGFA signaling pathway, which isinvolved in tumor-derived angiogenesis [22]. It was the
first FDA-approved drug for the treatment of metastatic
colon cancer and advanced non-small cell lung cancer
[23,24]. Because of their relatively low cytotoxicity, antian-
giogenic drugs may be used repeatedly and for long-term
cancer therapy. Tumor-driven angiogenesis is a nearly
universal characteristic of cancer, suggesting that antian-
giogenic drugs may have a wide range of clinical applica-
tions for cancer therapy [25]. Three major strategies that
have been explored so far are as follows: 1) blockade of
pro-angiogenic growth factors and their specific signaling
pathways, 2) enhancement of the levels of antiangiogenic
factors, and 3) disruption of abnormal cancerous vascular
function [25]. The aim of this study was to validate EEGS
as a potential antiangiogenic agent because the source of
EEGS, the Gleditsia sinensis thorn, is a herbal drug that
has been commonly prescribed for thrombosis and
tumor-related diseases in the traditional Korean medicine.
The antiangiogenic potential of EEGS was explored using
well established in vitro/in vivo angiogenesis assays.
Angiogenesis is a multi-step process requiring coordi-
nated endothelial functions, such as cell migration, pro-
liferation and extracellular matrix remodeling [16]. In
this study, we employed HUVEC cells for in vitro assays
representing several angiogenic functions because they
are a well-known macrovasculature model and are sus-
ceptible to antiangiogenic drugs [26]. Our in vitro assays
demonstrated that EEGS inhibited HUVEC cell prolif-
eration (Figure 1A) and cellular mobility (Figure 2A).
These cellular processes are related to the angiogenic
properties of HUVEC cells, and inhibition of these
angiogenic properties by EEGS resulted in global inhib-
ition of HUVEC cell tube formation on matrigel at EEGS
concentrations of ≥50 μg/mL for tube branching and
≥100 μg/mL for both tube branching and length
(Figure 2B). EEGS-mediated inhibition of the angiogenic
functions of HUVEC cells was replicated in the direct
in vivo angiogeneis assays using nude mice (Figure 3).
Cell growth, which is determined by the balance be-
tween cell amplification and death, affects angiogenesis.
To rule out the effect of EEGS-induced cytotoxicity on
angiogenesis, we investigated the cytotoxicity of EEGS in
HUVEC cells in the presence of increasing concentra-
tions of drug, up to 200 μg/mL. Although EEGS induced
dramatic antiproliferative effects at a concentration of
≥50 μg/mL (Figure 1A), cell viabilities was not signifi-
cantly changed at doses as high as 200 μg/mL, as
determined by membrane integrity or morphological
observation (Figure 1B and C). These results indicate
that the antiangiogenic potential of EEGS is not due to
cytotoxicity. Therefore, we can separate the antiangio-
genic effects of EEGS from its cytotoxic effect within
the range of concentrations used in this study (0–200
μg/mL). Paclitaxel, a microtubule-damaging anticancer
EEGS ( g/mL)









































































































































Figure 4 Down-regulation of proangiogenic proteins by EEGS in HUVEC cells. (A) HUVEC cells were incubated in the presence (100 μg/ml)
or absence of EEGS for 8 h. The protein expression profiles in the cultured medium and cell lysates were analyzed using a human angiogenesis
array kit. The closed and dotted rectangles represent the duplicated EDN1 and FGF2 spots in the proteome membrane chips, respectively.
(B) HUVEC cells were treated with increasing concentrations (0–200 μg/mL) of EEGS for 24 h. The amount of EDN1 released into the cultured
medium after EEGS treatment was quantified by immunoassay (left). Changes in EDN1 mRNA expression levels were determined by RT-PCR
(right). Total RNAs and cDNAs were prepared from HUVEC cells that were treated with increasing concentrations of concentrations of EEGS
for 8 h. (C) Changes in MMP2 activity in the HUVEC cultured medium were measured by gelatinolytic zymogram analysis (left). MMP2
activity was observed at the expected molecular weight (67 kDa) on the gelatin-incorporated SDS-PAGE gel. Coomassie staining of a SDS-
PAGE gel without gelatin confirmed equal protein loading. The MMP2 active bands were confirmed by western blot analysis. The effect of
EEGS on the levels of intracellular MMP2 mRNA was determined by RT-PCR (right). Total RNAs and cDNAs were prepared from HUVEC cells
that had been treated with increasing concentrations of EEGS for 8 h. Data are presented as the mean±S.D. of at least three independent
experiments. **p<0.01 and ***p<0.001 compared with control treatment.
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high concentrations, paclitaxel exerts cytotoxic effects by
inducing mitochondria-mediated apoptosis; however, at
low concentrations, it induces cytostatic effects by slowing
down the cell cycle, which is associated with antiangiogenicactivity in endothelial cells [26]. The inhibitory effect of
EEGS on angiogenic functions in HUVEC cells appeared
to be reversible because removal of EEGS was sufficient to
release cells from EEGS-induced cell migration arrest (data
not shown). Recently, Lu et al. (2012) [27] reported that
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sinensis fruits (gleditsiosides B, I, J, O, Q, and B) exerted
in vitro antiangiogenic effects on HUVEC cells. However,
they also showed that the active saponin compounds
induced significant apoptotic cell death in HUVEC cells by
enhancing caspase 3/8 expression, which were quite differ-
ent results from ours. Therefore, our data suggest that the
antiangiogenic potential of EEGS may come from active
constituent(s) other than saponin compounds.
Proteomic and immunoassay studies showed that both
intracellular and extracellular levels of EDN1 were
decreased by EEGS treatment in a dose-dependent man-
ner (Figure 4A and B). Furthermore, intracellular EDN1
mRNA levels correlated with changes in extracellular
EDN1 levels. EDN1 is one of three 21-amino acid pep-
tide family members (EDN1, EDN2, and EDN3) [28],
and it is known to be a proangiogenic modulator that
promotes endothelial cell proliferation and migration
through two G protein coupled receptors (ETAR and
ETBR) [16]. EDN1 is also known to have effects on the
growth and progression of various tumor types by
affecting proliferation and resistance to apoptosis [28].
In our study, EEGS treatment reduced the extracellular
and intracellular levels of EDN1, suggesting that redu-
cing EDN1 is one of the mechanisms by which EEGS
inhibits the angiogenic functions of HUVEC cells.
Because some effective antitumor agents targeting
tumor vessel formation have been shown to reduce
MMP2 activity [29,30] and MMP2 produced by endo-
thelial cells is known to contribute to the progress of
angiogenesis [17], we investigated MMP2 enzyme activ-
ity in response to EEGS treatment. The activity of extra-
cellular MMP2 was decreased by EEGS treatment in a
dose-dependent manner (Figure 4C). Each regulatory
step, such as transcription, translation, translational modi-
fication or extracellular secretion of expressed proteins
can affect MMP2 activity in cultured media. In the present
study, we observed that the decrease in MMP2 activity in
HUVEC cell cultured media correlated with decreased
levels of extracellular MMP2 proteins (Figure 4C, left
panel) and intracellular MMP2 mRNA (Figure 4C, right
panel). Therefore, EEGS down-regulates MMP2 mRNA
expression, leading to reduced MMP2 protein. However,
we did not investigate the mechanism by which EEGS
treatment down-regulates MMP2 mRNA expression in
the present study. It is possible that EEGS inhibits the
transcription of MMP2 or affects the stability of MMP2
mRNA in HUVEC cells. Taken together, our data suggest
that EEGS exerts its antiangiogenic effects on HUVEC
primary endothelial cells by inhibiting the expression and/
or activity of proangiogenic proteins.
Most previous phytochemical studies on Gleditsia
sinensis were carried out using its fruit and anomalous
fruit parts. The single compounds from the fruits oranomalous fruits of Gleditsia sinensis have been isolated
as triterpene (echinocystic acid), flavonoid (aromaden-
drin), polyphenol (ellagic acid glycosides), and triterpenoid
saponins (gleditsioside A-K, N-Q, and Z) [31-40]. Their
identified pharmacological activities were antagonistic
against dopamine D1 receptor (gleditsioside F) [33], pro-
tective against acute myocardial ischemia (echinocystic
acid) [32] or type 2 diabetes mellitus (aromadendrin) [35],
antiallergic in mast cells (saponins) [41], and cytotoxic to
leukemic cells (gleditsioside E) [38]. The single com-
pounds from the Gleditsia sinensis thorns were isolated as
a lupane acid with anti-HIV activity [42], and triterpenoid
(D:C-friedous-7-en-3-one) and sterols with antimutagenic
activity [43]. To our knowledge, there was no study
reporting antiangiogenic active compound(s) from the
Gleditsia sinensis. We are trying to identify antiangiogenic
active single compound(s) from the extract of Gleditsia
sinensis thorn using in vitro activity-guided fractionation.Conclusions
Because tumor angiogenesis is a very complex progress in-
volving diverse cell types, agents with multi-targets or a
combination of targeted single agents are needed to target
angiogenesis as an anticancer strategy. In vitro and in vivo
assays clearly identified EEGS as an antiangiogenic herbal
drug. Thus, EEGS is a promising antiangiogenic cancer
drug that warrants further development. The inhibitory
effects of EEGS are likely due to down-regulation of intra/
extracellular proangiogenic modulators, such as EDN1
and MMP2 enzymes. At present, the mechanisms by
which EEGS suppresses the expression of proangiogenic
modulators were not fully characterized in this study.
Further studies are needed to identify the molecule(s)
responsible for EEGS-mediated antiangiogenesis.Competing interests
The authors have declared that there is no competing interest.Authors' contributions
JMY and NSK carried out study concept, experimental design, data
acquisition and analysis, and drafted the manuscript. JSP and SMO carried
out data acquisition and analysis, and assisted with drafting manuscript. JL,
JK, and DSO assisted with study concept, drafting, and revising the
manuscript. OSB supervised the study and assisted with study concept and
revising the manuscript. All authors read and approved the final manuscript
for submission.Acknowledgements
The authors sincerely thank Dr. Go Ya Choi, Dr. Sungwook Chae, and Hye
Won Lee (Herbal Medicine Research Division, KIOM) for the identification of
Gleditsia sinensis thorns and preparation of the herbal extract. This research
was supported by a grant from the Korea Institute of Oriental Medicine
(KIOM, K12061).
Received: 30 July 2012 Accepted: 29 November 2012
Published: 4 December 2012
Yi et al. BMC Complementary and Alternative Medicine 2012, 12:243 Page 10 of 10
http://www.biomedcentral.com/1472-6882/12/243References
1. Matsunaga N, Chikaraishi Y, Shimazawa M, Yokota S, Hara H: Vaccinium
myrtillus (bilberry) extracts reduce angiogenesis In vitro and In vivo.
Evid Based Complement Alternat Med 2010, 7:47–56.
2. Tandle A, Blazer DG 3rd, Libutti SK: Antiangiogenic gene therapy of
cancer: recent developments. J Transl Med 2004, 2:22.
3. Papetti M, Herman IM: Mechanisms of normal and tumor-derived
angiogenesis. Am J Physiol Cell Physiol 2002, 282:C947–C970.
4. Tosetti F, Ferrari N, De Flora S, Albini A: Angioprevention: angiogenesis is a
common and key target for cancer chemopreventive agents. FASEB J
2002, 16:2–14.
5. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med
1971, 285:1182–1186.
6. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of
experimental cancer does not induce acquired drug resistance. Nature
1997, 390:404–407.
7. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.
Nat Med 2003, 9:669–676.
8. Dai Y, Chan YP, Chu LM, Bu PP: Antiallergic and anti-inflammatory
properties of the ethanolic extract from gleditsia sinensis. Biol Pharm Bull
2002, 25:1179–1182.
9. Lai P, Du JR, Zhang MX, Kuang X, Li YJ, Chen YS, He Y: Aqueous extract of
gleditsia sinensis Lam. Fruits improves serum and liver lipid profiles and
attenuates atherosclerosis in rabbits fed a high-fat diet. J Ethnopharmacol
2011, 137:1061–1066.
10. Lee SJ, Park K, Ha SD, Kim WJ, Moon SK: Gleditsia sinensis thorn extract
inhibits human colon cancer cells: the role of ERK1/2, G2/M-phase cell
cycle arrest and p53 expression. Phytother Res 2010, 24:1870–1876.
11. Long L, Geng GX, Li QW: Effect of gleditsia sinensis stings on growth
inhibition and expression of PCNA and p53 in mice bearing uterine
cervical carcinoma (U14). Zhongguo Zhong Yao Za Zhi 2006, 31:150–153.
12. Chui CH, Lau FY, Chan AS, Cheng GY, Wong RS, Lai KB, Kok SH, Yeung TT,
Teo IT, Yau MY, et al: Gleditsia sinensis fruit extract-induced apoptosis
involves changes of reactive oxygen species level, mitochondrial
membrane depolarization and caspase 3 activation. Int J Mol Med 2005,
15:539–543.
13. Pak KC, Lam KY, Law S, Tang JC: The inhibitory effect of gleditsia sinensis
on cyclooxygenase-2 expression in human esophageal squamous cell
carcinoma. Int J Mol Med 2009, 23:121–129.
14. Lee SJ, Park SS, Kim WJ, Moon SK: Gleditsia sinensis thorn extract inhibits
proliferation and TNF-alpha-induced MMP-9 expression in vascular
smooth muscle cells. Am J Chin Med 2012, 40:373–386.
15. Asakage M, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Yamada J, Okaji
Y, Kaisaki S, Osada T, Takahashi K, et al: Sulforaphane induces inhibition of
human umbilical vein endothelial cells proliferation by apoptosis.
Angiogenesis 2006, 9:83–91.
16. Salani D, Taraboletti G, Rosano L, Di Castro V, Borsotti P, Giavazzi R, Bagnato
A: Endothelin-1 induces an angiogenic phenotype in cultured
endothelial cells and stimulates neovascularization in vivo. Am J Pathol
2000, 157:1703–1711.
17. Cardenas C, Quesada AR, Medina MA: Anti-angiogenic and anti-
inflammatory properties of kahweol, a coffee diterpene. PLoS One 2011,
6:e23407.
18. Wong KK: Searching for a magic bullet in NSCLC: the role of epidermal
growth factor receptor mutations and tyrosine kinase inhibitors. Lung
Cancer 2008, 60(Suppl 2):10–18.
19. Dimitrov DS, Marks JD: Therapeutic antibodies: current state and future
trends–is a paradigm change coming soon? Methods Mol Biol 2009,
525:1–27.
20. Baguley BC: Multiple drug resistance mechanisms in cancer.
Mol Biotechnol 2010, 46:308–316.
21. Folkman J, Merler E, Abernathy C, Williams G: Isolation of a tumor factor
responsible for angiogenesis. J Exp Med 1971, 133:275–288.
22. Lord S, Harris AL: Angiogenesis - still a worthwhile target for breast
cancer therapy? Breast Cancer Res 2010, 12(Suppl 4):19.
23. Planchard D: Bevacizumab in non-small-cell lung cancer: a review. Expert
Rev Anticancer Ther 2011, 11:1163–1179.
24. Scott LJ: Bevacizumab: in first-line treatment of metastatic breast cancer.
Drugs 2007, 67:1793–1799.
25. Kumaran G, Clamp AR, Jayson GC: Angiogenesis as a therapeutic target in
cancer. Clin Med 2008, 8:455–458.26. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, Braguer D:
Antiangiogenic activity of paclitaxel is associated with its cytostatic
effect, mediated by the initiation but not completion of a mitochondrial
apoptotic signaling pathway. Mol Cancer Ther 2004, 3:1301–1310.
27. Lu D, Xia Y, Tong B, Zhang C, Pan R, Xu H, Yang X, Dai Y: In vitro anti-
angiogenesis effects and active constituents of the saponin fraction
from gleditsia sinensis. Integr Cancer Ther 2012,
doi:10.1177/1534735412442377.
28. Bagnato A, Rosano L: The endothelin axis in cancer. Int J Biochem Cell Biol
2008, 40(8):1443–1451.
29. Miyake JA, Benadiba M, Colquhoun A: Gamma-linolenic acid inhibits both
tumour cell cycle progression and angiogenesis in the orthotopic C6
glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1,
pRb, p53 and p27 protein expression. Lipids Health Dis 2009, 8:8.
30. Lu MK, Chen PH, Shih YW, Chang YT, Huang ET, Liu CR, Chen PS: Alpha-
chaconine inhibits angiogenesis in vitro by reducing matrix
metalloproteinase-2. Biol Pharm Bull 2010, 33:622–630.
31. Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Four new triterpenoidal
saponins acylated with one monoterpenic acid from gleditsia sinensis.
J Nat Prod 1999, 62:740–745.
32. Wu J, Li J, Zhu Z, Huang G, Tang Y, Gao X: Protective effects of
echinocystic acid isolated from gleditsia sinensis Lam. Against acute
myocardial ischemia. Fitoterapia 2010, 81:8–10.
33. Yu S, Park JS, Paredes V, Song MC, Baek NI, Lee SI, Lim JS, Cho NY, Yoon J,
Baek K: Screening and isolation of a natural dopamine D1 receptor
antagonist using cell-based assays. J Biotechnol 2010, 145:304–309.
34. Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Triterpenoidal saponins
from gleditsia sinensis. Phytochemistry 1999, 52:715–722.
35. Zhang WY, Lee JJ, Kim IS, Kim Y, Myung CS: Stimulation of glucose uptake
and improvement of insulin resistance by aromadendrin. Pharmacology
2011, 88:266–274.
36. Zhou L, Li D, Jiang W, Qin Z, Zhao S, Qiu M, Wu J: Two ellagic acid
glycosides from gleditsia sinensis Lam. With antifungal activity on
magnaporthe grisea. Nat Prod Res 2007, 21:303–309.
37. Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Gleditsiosides N-Q, new
triterpenoid saponins from gleditsia sinensis. J Nat Prod 1999, 62:877–881.
38. Zhong L, Qu G, Li P, Han J, Guo D: Induction of apoptosis and G2/M cell
cycle arrest by gleditsioside E from gleditsia sinensis in HL-60 cells.
Planta Med 2003, 69:561–563.
39. Gao ZZ, Xia YF, Yao XJ, Dai Y, Wang Q: A new triterpenoid saponin from
gleditisia sinensis and structure-activity relationships of inhibitory effects
on lipopolysaccharide-induced nitric oxide production. Nat Prod Res 2008,
22:320–332.
40. Zhang Z, Koike K, Jia Z, Nikaido T, Guo D, Zheng J: Triterpenoidal saponins
acylated with two monoterpenic acids from gleditsia sinensis. Chem
Pharm Bul 1999, 47:388–393.
41. Chong W, Feng XY, Zhen GZ, Dan L, Yue D: Inhibition of mast cell
degranulation by saponins from gleditsia sinensis–structure-activity
relationships. Nat Prod Commun 2009, 4:777–782.
42. Li WH, Zhang XM, Tian RR, Zheng YT, Zhao WM, Qiu MH: A new anti-HIV
lupane acid from Gleditsia sinensis Lam. J Asian Nat Prod Res 2007,
9:551–555.
43. Lim JC, Park JH, Budesinsky M, Kasal A, Han YH, Koo BS, Lee SI, Lee DU:
Antimutagenic constituents from the thorns of gleditsia sinensis.
Chem Pharm Bul 2005, 53:561–564.
doi:10.1186/1472-6882-12-243
Cite this article as: Yi et al.: Ethanol extract of Gleditsia sinensis thorn
suppresses angiogenesis in vitro and in vivo. BMC Complementary and
Alternative Medicine 2012 12:243.
